TC-2216
From Wikipedia, the free encyclopedia
Jump to: navigation, search
![]() |
|
Systematic (IUPAC) name | |
---|---|
8-pyridin-3-yl-1,8-diazaspiro[4.4]nonane
|
|
Identifiers | |
PubChem | CID 10176607 |
ChemSpider | 8352112 |
Chemical data | |
Formula | C12H17N3 |
Molar mass | 203.283 |
3D model (Jmol) | Interactive image |
|
|
|
|
(verify) |
TC-2216 is a drug developed by Targacept which acts as a partial agonist at neural nicotinic acetylcholine receptors and is being researched for the treatment of anxiety and depression.[1]
References[edit]
- ^ Romanelli, M.; Gratteri, P.; Guandalini, L.; Martini, E.; Bonaccini, C.; Gualtieri, F. (2007). "Central nicotinic receptors: structure, function, ligands, and therapeutic potential". ChemMedChem. 2 (6): 746–767. doi:10.1002/cmdc.200600207. PMID 17295372.
|
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||
|
5-HT1A agonists | |
---|---|
GABAAR PAMs |
|
α2δ VDCC blockers | |
Antidepressants |
|
Sympatholytics | |
Others |
|
|||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
|
|||||||||||||||||
|
Retrieved from "https://en.wikipedia.org/w/index.php?title=TC-2216&oldid=748519965"
Hidden categories: